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Abstract
Total pancreatectomy (TP) was abandoned by many surgeons because of its lack of benefits and other
major drawbacks. The potential benefits of TP, including its oncological as well as its technical advan-
tages, did not prove to be valid. Problems associated with insulin-deprived diabetes mellitus and high
perioperative morbidity and mortality rates were not easily manageable. However, in the new era of
pancreatic surgery, new indications for TP have been defined. These have been paralleled by improve-
ments in surgical technique, multidisciplinary management and postoperative intensive care. These
factors have transformed TP into a safe and reasonable surgical procedure with excellent perioperative
morbidity and mortality, as well as good longterm outcome. We review the indications for TP and describe
our operative technique in detail.
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Introduction
Pancreatic surgery remains a challenging procedure which
may involve several organs and can require vascular reconstruc-
tion. Its complexity is underlined by the value of centralizing
pancreatic surgery to high-volume hospitals.1–7 Total pancreate-
ctomy (TP) for pancreatic cancer was first reported by Rockey in
1943.8 Subsequently, it was considered that partial pancreatec-
tomy (PP) would help to circumvent pancreatic fistula.9 Because
of high tumour recurrence rates after Kausch–Whipple pro-
cedures, any suggestion of possible tumour multicentricity
supported a role for TP as a means of achieving R0 resection.
Subsequent studies demonstrated no improvement in post-
operative outcome and major metabolic problems were found
to occur.10–12 These were difficult to address and the procedure
fell out of favour. However, recent studies have demonstrated
progress regarding postoperative outcomes of TP.13,14 In addi-
tion, new pancreatic tumour entities have been identified in
the past decade and these require total rather than partial
pancreatectomy.
Indications
As operative techniques and peri- and postoperative management
strategies have evolved, the indications for TP in pancreatic cancer
changed. Indications for TP, as perceived by ourselves and
others,15–19 are described below.
The R0 resection
As many patients suffer from local recurrence, tumour resection
with negative margins constitutes an important prognostic
indicator.20–23 In patients undergoing PP for pancreatic cancer, TP
improves survival in isolated neck margin-positive patients and is
associated with survival benefit. Because peri- and postoperative
complication rates are comparable with those for PP, TP is recom-
mended in cases in which cancer has spread to the left part of the
pancreas.24
Pancreatic anastomosis that is likely to leak
Pancreatic fistula (PF) is a major complication of PP; however,
its incidence in high-volume centres is reported to be very low,
ranging between 2% and 5%.18,25–27 Even if PF becomes evident, up
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to 85% of patients with PF can be managed by conservative or
interventional methods.28 However, PF can lead to sepsis and, via
the erosion of vessels, to life-threatening haemorrhage. Such com-
plications and their accompanying sequelae may not respond to
conservative treatment and surgical intervention (completion
pancreatectomy) may be necessary. Completion pancreatectomy
in this critically ill patient population is accompanied by an
unfavourable mortality rate of up to 39%.14
Although there is no consensus on the technique for safe
pancreatic anastomosis,25,29 the prognostic factors for pancreatic
anastomosis failure are well known30 and include dilatation of
the pancreatic duct,31,32 texture of the pancreatic tissue,33 surgical
technique (traumatic [high blood loss] vs. meticulous and tissue-
sparing),34 and extent of resection (multivisceral vs. standard radi-
cal).32 In technically challenging intraoperative situations, these
prognostic factors may help the surgical team to decide whether
a TP should be performed to avoid a likely PF. In certain clinical
situations it is desirable to prevent any need for emergency
completion pancreatectomy and, instead, to perform an elective
TP when multiple unfavourable prognostic factors for pancreatic
anastomosis exist.
Hereditary pancreatic cancer
Hereditary pancreatic cancer (HPC) is a rare genetic disease
caused by mutations of the trypsinogen cationic gene on chromo-
some 7.35 In a recent report, Rebours et al. evaluated 78 families
(200 patients) with HPC in an exhaustive national series and
found their relative risk for pancreatic cancer to be 87 times higher
than that in the general population.36 It has been suggested that
surveillance be performed for the early detection of cancer or
intraepithelial neoplasia in these high-risk individuals. Patients
with two or more first-degree relatives with pancreatic cancer, one
first-degree relative with cancer diagnosed before the age of 50
years, or two or more second-degree relatives with cancer, one of
whom was diagnosed before the age of 50 years, are considered
to be at high-risk.33 Patients for resection should be carefully
selected. In high-risk patients, evidence of lesions suspected
of being dysplastic, diagnosed by contrast-enhanced computed
tomography, endoscopic retrograde cholangiopancreatograpy
(ERCP), ultrasonography or endoscopic ultrasonography, may
help to determine the timing of surgery.37 The key is to diagnose
dysplastic lesions before they develop into invasive cancer. It may
be reasonable to initiate surveillance when the subject is 5–10
years younger than the age at which his or her youngest affected
relative was diagnosed with the onset of pancreatic cancer, or at
the onset of symptoms such as weight loss, pain or development
of diabetes. In patients with widespread and multifocal pancreatic
intraepithelial neoplasia (PanIN) changes throughout the pan-
creas, prophylactic TP should be considered to avert the develop-
ment of pancreatic carcinoma.38
Intraductal papillary mucinous neoplasm (IPMN)
The definition of intraductal papillary mucinous neoplasm
(IPMN) was introduced by the World Health Organization in
1996 to describe a potentially malignant disease. These neoplasms
are connected to the ductal system and can be subclassified into
main and branch duct types and a mixed type that contains
elements of both. Classification can be made based on ERCP,
imaging studies or histology.39 The natural history of IPMNs and
their current management have been reviewed in detail recently
by Bassi et al.40 and Wente et al.41 Early changes are considered to
be premalignant. The recurrence rate of invasive IPMNs in the
published literature is 25–100%.42–45 However, recurrences of non-
invasive IPMNs are rare. Based on the available literature, main
duct IPMNs should be resected whenever possible because of the
high prevalence of malignancy. By contrast, asymptomatic branch
duct IPMNs with no mural nodules and which are <3 cm in
diameter may be followed by cross-sectional imaging,46 although
this strategy is under dispute because up to 20% of IPMNs
become malignant within 8 years. During PP for main duct
disease, TP should be performed to ensure R0 resection if severe
dysplasia or invasive cancer is evident at the resection margin.
In the surgical treatment of multicentric branch duct disease,
TP should be performed in the first place.
Surgical technique
A single administration of antibiotics is given just before the onset
of the surgical procedure and repeated if the duration of surgery
exceeds 4 h. The abdomen can be opened by a midline or bilateral
subcostal incision. Exposure must be adequate and laparotomy
includes inspection of the liver and peritoneum. A careful search
for lymph nodes is made in the mesenteric root, hepatoduodenal
ligament and common hepatic artery. Palpation of the head and
the uncinate process of the pancreas in relation to the mesenteric
vessels and, particularly, the region of duodenojejunal flexure
can demonstrate signs of non-resectability. A biopsy of suspicious
areas is taken for intraoperative frozen section histology.
If no contraindication for resection is found, the hepatic
and splenic flexures of the colon are mobilized. A wide ‘Kocher
manoeuvre’ of the duodenum and head of the pancreas is
undertaken to provide exposure. To allow complete access to the
anterior surface of the pancreas, the lesser sac is opened, either by
dividing the gastrocolic omentum or by separating the greater
omentum from the transverse colon. After visualization of the
pancreas, the lower border is mobilized by separating the adhe-
sions to the transverse colon mesentery. The superior mesenteric
vein is identified, dissected and followed to its passage behind the
pancreas. Here the surgeon is able to evaluate for vessel infiltra-
tion. In cases of portal or superior mesenteric vein involvement,
it has been demonstrated that in resection with curative intent,
vascular resection can be performed without increased morbidity
and mortality.47–51 We have previously described in detail the
technique of portal vein resection in locally advanced pancreatic
cancer.52 Above the pancreas, the dissection of the vessels supply-
ing the liver is performed with critical assessment of vascular
involvement. Care should be taken if a displaced or accessory right
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hepatic artery is present. If resectability is questionable, complete
dissection and exploration of the common and proper hepatic
artery (PHA) is necessary.
If no contraindication for resection is evident, a cholecy-
stectomy is performed, and the cystic artery divided. A complete
lymphadenectomy of the hepatoduodenal ligament is performed
at the time when the common bile duct is divided proximal to the
cystic duct. During dissection of the hepatoduodenal ligament,
the left, right and proper hepatic arteries are identified and
exposed. Even in pylorus-preserving pancreatectomy, we divide
the right gastric artery and complete the lymphadenectomy until
the gastroduodenal artery is reached. To assess whether a further
reconstruction is required for a coeliac trunk stenosis, we occlude
the gastroduodenal artery before dividing it and check the pulse
on the PHA. If a sufficient flow is present, the gastroduodenal
artery is divided and the lymphadenectomy of the common
hepatic artery and coeliac trunk towards the right is completed.
The complete dissection and lymphadenectomy of the hepa-
toduodenal ligament lead to clear exposure of the portal vein,
which can be followed until it disappears behind the upper border
of the pancreas, as indicated in Fig. 1. The posterior superior
pancreaticoduodenal vein, which ends on the upper border of the
pancreas from the right side into the portal vein, is divided
securely. In the case of a negative proximal duodenal resection
margin, and no evidence of tumour infiltration of the peripyloric
lymph nodes, a pylorus-preserving procedure is performed.
Therefore, the right gastroepiploic artery is divided. We try to
preserve the coronary vein (left gastric vein) if it is a branch of the
main portal vein. After resection of the splenic vein, the coronary
vein may ensure sufficient venous drainage of the stomach. If
venous congestion of the stomach occurs, a subtotal gastrectomy
may be necessary. Approximately 4 cm beyond the pylorus, the
duodenum is divided by a linear stapling device. To improve
access to the pancreas, the stomach is displaced towards the left
upper abdomen. Then, the ascending part of the duodenum is
divided by a linear stapler. Preservation of the spleen is considered
whenever possible. However, if splenectomy is necessary to ensure
radicality, the splenorenal ligament is divided and the splenic vein
and artery are ligated. Whereas the splenic artery can be located
along the upper border of the pancreas, the splenic vein can easily
be identified behind the pancreas (Figs 2, 3A, B). After division of
the short gastric vessels and the inferior mesenteric vein, en bloc
resection is performed together with the pancreas, duodenum
and the peripancreatic lymph nodes (Fig. 4). For this purpose, the
plane of dissection lies first towards the superior mesenteric artery
(SMA). The artery is followed cranially until its origin at the aorta,
resecting lymph nodes anterior to the aorta, between the coeliac
artery and SMA, as well as those to the left of the SMA. As the
dissection continues to the left, the adrenal vein and the adrenal
gland become part of the posterior plane, and the renal vein
becomes the inferior border of dissection. Further laterally, dis-
section is continued to the Gerota’s fascia of the superior half of
the kidney (Fig. 5).
For reconstruction after TP a suitable jejunal loop is prepared.
Small bowel is displaced to the right and the transverse colon
cranially, leading to exposure of the duodenojejunal flexure. The
ligament of Treitz is divided and the proximal 10–15 cm of the
jejunum is dissected and resected. The second jejunal loop is
carefully dissected and left with a suitable vascular arcade. To
prevent an internal hernia, the space behind the superior mesen-
teric vessels is closed by suture. The prepared jejunal loop is then
transposed retrocolically through the transverse mesocolon to
Figure 1 Intraoperative image after complete dissection of the hepa-
toduodenal ligament and coeliac trunk. The duodenum is divided
and the stomach is displaced cranially to the left. HD, hepatic duct;
PV, portal vein; PHA, proper hepatic artery; LGA, left gastric artery;
SA, splenic artery
Figure 2 Intraoperative image demonstrating the mobilization of the
body of the pancreas. PV, portal vein; SMV, superior mesenteric vein;
SV, splenic vein; IMV, inferior mesenteric vein
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perform the end-to-side hepaticojejunostomy at a minimal
opening on the antimesenteric side from the jejunum by a single-
layer technique (Fig. 6). We fix the mucosa of the jejunum to the
circular opening with 6-0 PDS® single stitches and perform the
anastomosis with 5–0 PDS® (with a c1 needle). Although adequate
mobilization of the bile duct is necessary to ensure a tension-free
anastomosis, pericholangic tissue must be preserved as much as
possible to maintain optimal blood supply. To finalize the recon-
struction, 50 cm distal to the hepatojejunostomy, we perform
an antecolic,53 end-to-side duodenojejunal anastomosis in a
two-layer continuous fashion. The opening in the transverse
mesocolon is closed by sutures and a drain is placed close to the
hepaticojejunostomy.
Results
We performed 147 TP procedures between October 2001 and
November 2006.14 Of the subjects, 114 suffered from malignant
(A)
(B)
Figure 3 (A) Intraoperative image demonstrating the complete
mobilization of the pancreas and spleen. Note that both are dis-
placed to the right, exposing the splenic vessels and the coeliac
trunk. (B) Magnification of (A). SV, splenic vein; SA, splenic artery;
CT, coeliac trunk; P, pancreas; LGA, left gastric artery
Figure 4 Intraoperative image demonstrating the dissection along
the portal vein. Note that the splenic artery is divided and the
pancreas is displaced to the left. PV, portal vein; CHA, common
hepatic artery; LGA, left gastric artery; SA, splenic artery; SMV,
superior mesenteric artery
Figure 5 En bloc resection including gall bladder, pancreas, duode-
num, spleen and part of the greater omentum
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pancreatic disease. In patients undergoing elective TP, hospital
mortality was < 5% and morbidity < 40%. Median survival was
21.9 months, and 1- and 3-year survival rates were 64.3% and
36.6%, respectively. A matched-pairs analysis was performed
between TP and PP patients to assess quality of life (QoL). Total
pancreatectomy patients had worse values in some parameters
concerning function and symptom scales compared with PP
patients. However, their global health status was no different and
overall QoL was acceptable. This is supported by a recent QoL
analysis which concluded that TP patients have a QoL similar
to that of patients with diabetes mellitus from other causes.54
Conclusions
Recent reports have demonstrated that modern treatment regi-
mens, interdisciplinary management and improved postoperative
care in TP patients result in longterm survival, QoL, mortality and
morbidity rates comparable with those of PP patients.13,14,24 Total
resection of the pancreas can lead to endocrine and exocrine
insufficiency with severe metabolic consequences, such as difficult
glycaemic control, malabsorption, steatohepatitis and liver failure.
However, these issues, like the term ‘brittle diabetes’, which
describes the unfavourable combination of insulin sensitivity and
hypoglycaemic unawareness and dates back to the 1930s,55 are
outdated and have been challenged. As recent data emphasize that
the longterm survival of patients undergoing TP is dependent on
the biology of the underlying cancer rather than on physiological
changes caused by the apancreatic state, this procedure should no
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